Hanid Audish

Dr. Hanid Audish of Encompass Clinical Research Discusses New High Blood Pressure Study

Dr. Hanid Audish and the team at Encompass Clinical Research have begun phase two of their newest study evaluating the efficacy and safety of CIN-107, a hypertension medication. This study will assess the effects of three oral doses of CIN-107 versus a placebo pill over the course of twelve weeks. CIN-107 is a new medication designed for patients with treatment-resistant hypertension who are unable to control their blood pressure levels. Hanid Audish MD and the Encompass team are currently recruiting test subjects for the study that meet specific criteria.

One of the biggest challenges for people with hypertension and other cardiovascular diseases is maintaining their goal blood pressure levels. This is especially difficult for those with treatment-resistant form of hypertension. Resistant hypertension, or RHTN, is defined as uncontrolled blood pressure despite the use of >3 anti-hypertensive agents of different classes, one of which must be a diuretic,…at maximally tolerated doses. Those with RHTN normally have 130/80mmHG, although this number depends on the individual. For those with hypertension, an RHTN diagnosis is especially concerning as it increases the likelihood of heart attack, kidney failure, and stroke.

The CIN-107 study will be the first of its kind, as the study drug is a new medication within a new class of medications. The study will be a “randomized, double-blind, placebo-controlled, dose-ranging Phase 2” study and will comprise of men and women with a seated BP of more than 130/80mmHg. The study members must be on a stable regimen of more than three anti-hypertensive agents (one of which is a diuretic) for four weeks prior to the study and have complied with at least 70% of their anti-hypertensive medication regimen.

The CIN-107 study is financed by the pharmaceutical company CinCor. CinCor is a clinical-stage biopharmaceutical company based in the Midwest. The CinCor company focuses on primarily cardiovascular, metabolic, and kidney disease medication. CIN-107, their newest lead program, is regarded as highly innovative based on its novel aldosterone synthase inhibitor. Aldosterone is an essential hormone in the adrenal gland that regulates salt and water in the body, thus greatly affecting blood pressure. CinCor and the Encompass Clinical Research team believe that CIN-107 testing should conclude by early 2021.

If you would like to learn more information about the CIN-107 study or Encompass Clinical Research, you can visit our site at www.encompassresearch.com.

Dr. Hanid Audish Performs Study for Treating Low Testosterone in Men

Low testosterone is an issue that is quite common, effecting as many as 4 in 10 men by the time they reach the age of 45. Noting the effects that low testosterone can have on men older than 45, doctors and researchers have contributed to the ongoing conversation to establish ways to treat individuals that may be suffering from it. Dr. Hanid Audish is part of one such study, researching if a topical administration of testosterone gel can help improve the symptoms of individuals with Low T.

Low blood testosterone is typically identified by a testosterone level that is less than 300 nanograms per deciliter. As men age, testosterone levels gradually drop about 1-2% per year and, by 45, a significant percentage of men may have what can be considered Low T. Dr. Hanid Audish acknowledges that many recognize that testosterone is a sex hormone, but some do not know that it is responsible for several crucial functions such as, the production of sperm and red blood cells, bone density, muscle mass, and more. Much of the urgency of studying low testosterone and ways that medical professionals combat the condition in patients stems from the impact that the condition can have on men’s lives if left unaddressed. For example, Dr. Hanid Audish notes that Low T (male hypogonadism) can cause symptoms such as erectile dysfunction, low sex drive, depression, irritability, fatigue, obesity, and loss of muscular strength.

Dr. Hanid Audish’s recent study for low testosterone includes men that are between the ages of 45 and 80 that have low serum testosterone concentrations (< 300 ng/dL), exhibit at least one of the signs or symptoms of hypogonadism, have evidence of cardiovascular disease, or are at an increased risk. The blinded and placebo-controlled study with AbbVie, Acerus Pharmaceuticals Corporation, Allergan Sales, LLC, Endo Pharmaceuticals, and Upsher-Smith Laboratories will assess topical testosterone replacement therapy in these men. The primary outcome measure is the time to major adverse cardiac event (MACE) while the secondary outcome measures of the study are to assess the cardiovascular safety of the treatment as well as the prostate safety. Dr. Hanid Audish notes that the study will also assess improvement in sexual activity, remission of depression, reduction of clinical fractures, correction of anemia, and reduction in progression from pre-diabetes to diabetes.

An estimated several million men in the United States have low testosterone and may suffer from any number of the symptoms linked to the condition. If you or a loved one has Low Testosterone and are interested in participating in a study or learning more, information can be found at www.encompassresearch.com.

Diabetes Diagnosis can still be Managed during Daily Life, says Hanid Audish, DO

A diagnosis of diabetes can come as a shock and prove life-changing for patients. From that day forward, these individuals will need to keep tabs on glucose levels in their blood and/or begin using insulin to make up for what their body has stopped producing. It’s not a terminal diagnosis, according to Hanid Audish, DO, but that shouldn’t take away from the severity of the condition. Hanid Audish, DO, principal investigator with Encompass Clinical Research in California, is an expert on medical matters related to clinical trials that can produce forms of primary care treatment. Given that current estimates from the U.S. Centers for Disease Control (CDC) place the number of Americans with diabetes at more than 30 million, additional research into disease will clearly be welcomed by many.

To help readers better understand the differences between the two types of diabetes, Hanid Audish, DO – who also spent 11 years as a family practice physician – will explain. Both types of diabetes are linked back to storage of glucose and how the body converts it into energy. According to MedicalNewsToday.com glucose that “collects in the blood and does not reach the cells that need it … can lead to serious complications.” Those suffering from either form of diabetes could be at risk of kidney disease, vision loss, blood vessel damage, cardiovascular disease and more.

An individual experiencing complications from type 1 diabetes is often a child or young adult, although those who are older are not immune from the diagnosis. By definition, type 1 diabetes involves the body’s immune system attacking insulin-producing beta cells in the pancreas. A patient with this form of the disease will “need to use supplemental insulin from the time they receive the diagnosis and for the rest of their life,” according to the article. It can be discouraging to receive such a diagnosis, but Hanid Audish, DO says there are a number of risk factors to keep in mind. These range from having a family history of the condition and exposure to other viruses to genetic defects that one was born with.

For those with type 2 diabetes, the body will stop making insulin and the glucose in one’s blood never enters the cells that need to be nourished. Additional insulin isn’t a requirement in the early stages and it may be possible to manage the condition through acts as simple as usage of medication, exercise and a healthy diet. Since Hanid Audish, DO’s background is in clinical testing, he is always interested in learning about new pharmaceutical forms of treatment when it comes to type 2 diabetes.

According to ClinicalTrials.gov, researchers from the Shanghai 10th People’s Hospital had recently looked at “the effect of probiotics on the improvement of glucose and lipid metabolism.” It’s these types of theories that drive favorable medical outcomes, says Hanid Audish, DO, who is board-certified by the American Osteopathic Board of Family Physicians in family medicine. Readers who would like additional information on clinical trials are encouraged to visit www.encompassresearch.com.

Hanid Audish, DO Closely Tracking Clinical Trials into Emerging COVID-19 Treatment Options

The spread of COVID-19 has gripped the attention of the general public who, until now, were likely largely unaware of how clinical trials produced proven healthcare strategies. The process of determining how a new drug or form of treatment can be deployed in the primary care arena is taken in careful steps. According to Hanid Audish, DO, who has spent the past decade with California’s Encompass Clinical Research, the spotlight is rapidly focusing on pharmaceutical companies. What’s more, federal data from ClinicalTrials.gov shows that attempts to understand interactions between existing drugs and coronavirus recovery rates are also increasing. Hanid Audish, DO, a physician in clinical research, has been the principal investigator with Encompass Clinical Research for the past three years. As such, he can offer additional insight into this specialized sector during the uncertainty of the coronavirus era.

Clinical trials encompass work that is conducted in phases and “designed to answer certain questions,” according to Cancer.org. These phases take the proposed treatment toward the inevitable — and hopeful — conclusion of being a viable treatment to be used by primary care doctors. Right now, patients diagnosed with mild coronavirus symptoms have had little recourse beyond self-quarantining at home. In more severe cases, Hanid Audish, DO has read about the use of the immune-suppressant hydroxychloroquine to manage the body’s response to viral infection. Many other researchers are working hard to produce tangible results and ClinicalTrials.gov, which deems the COVID-19 pandemic “an emerging, rapidly evolving situation,” is publishing the fruits of their labor.

Ongoing work sponsored by the Shahid Beheshti University of Medical Sciences is looking at hydroxychloroquine and three other drugs in hopes of providing patients with access to the strongest anti-viral properties as possible. The work, which has reached phase 2 of clinical trials, involved 60 randomized participants from the Loghman Hakim Medical Education Center in Tehran who’d tested positive for COVID-19. While the final results of the study have yet to be finalized, researchers state that their findings will be published “in the form of an article in a reputable international journal.”

Such research is of great interest to Hanid Audish, DO, as he and Encompass Clinical Research are in constant contact with pharmaceutical companies to discuss new opportunities. His firm is mostly involved in phase 2-4 trials so the work from Shahid Beheshti University of Medical Sciences is even more relevant to him. With a decades-long career in science, medicine and biology, Hanid Audish, DO will continue to contribute to these sectors through clinical testing in during an era of great public need. If you would like additional information on clinical trials, please visit www.encompassresearch.com.

Recent Study Links Yoga Practice to Migraine Relief

Based in San Diego, Hanid Audish, DO, is an established medical researcher who guides Encompass Clinical Research and focuses on conditions such as osteoarthritis and diabetes mellitus. Another area in which Dr. Hanid Audish has extensive knowledge is migraines, including their symptoms and treatments.

Often triggered by stress, migraines typically involve an intense throbbing or pulsating pain in one area of the head. While medications are a first-line treatment, they are only effective in about half of all migraine cases.

One recent study undertaken in New Delhi at the All India Institute of Medical Sciences focused on the potential of yoga, along with medication, in alleviating migraine symptoms. The study involved 114 participants divided into two groups: those who only took medications, and those who supplemented drugs with a month of three sessions of guided yoga per week. Over the next 2 months, those in the latter group continued to practice the hour-long yoga routines at home five times a week.

The results showed that approximately 12 percent of those in the yoga group reached headache-free status at the culmination of the 3-month study. This contrasted with no headache-free participants among those who only took medications.

The Four Stages of Osteoarthritis

A principal investigator at Encompass Clinical Research in California, Hanid Audish, DO oversees clinical trials at the company in addition to delegating tasks to staff and documenting trial progression. At his company, Dr. Hanid Audish and his team are currently involved in a study relating to osteoarthritis.

The most commonly diagnosed joint arthritis disease, osteoarthritis affects joint functionality and affects the knees, hands, and hips. With knee osteoarthritis, there are four stages of development, in addition to stage 0, which is assigned to a normal, healthy knee. Each of these four stages is briefly described below:

Stage 1 – Minor – People diagnosed with stage 1 knee osteoarthritis often do not experience any pain or discomfort due to the minor wear on the knee joint. If they do experience pain, such sensations can be relieved with over-the-counter (OTC) medications. At this stage, physicians may suggest that patients take supplements and employ certain exercises that slow the progression of osteoarthritis.

Stage 2 – Mild – By this stage, x-ray images of the knee joints will show greater bone spur growth. However, the amount of cartilage in the joint is still a healthy size. This means the bones are not scraping against one another, but the existence of the bone spurt can cause some discomfort and stiffness in the knee.

Stage 3 – Moderate – The cartilage between the knee joints begins eroding by stage 3 osteoarthritis. As this occurs, the surface between the bones and cartilage narrows, thus leading to more joint inflammation, stiffness, and popping sounds. Patients with this stage of osteoarthritis can take OTC pain relievers, but their physician may also prescribe pain relievers or recommend they receive corticosteroid injections.

Stage 4 – Severe – People at this stage often require surgery to realign or replace their joint because the cartilage has either entirely disappeared or significantly diminished. Due to the lack of cartilage, moving the knee joint is very stiff and sometimes impossible.

Clinical Trials – FAQ

Dr. Hanid Audish is a principal researcher at Encompass Clinical Research, a Spring Valley, California-based clinical research site. Among the tools that Dr. Hanid Audish uses are comprehensive clinical trials. As important as these trials are for valid medical research, many people don’t quite understand how they work.

Here are answers to some common questions that arise about clinical trials.

Q: What is a clinical trial?
A: A research study, typically in a health-related field, that follows a predefined protocol to reach conclusions about treatments and interventions for specific conditions.

Q: Who can participate in clinical trials?
A: Every trial is carefully designed to reach results germane to the research focus. Thus, trial groups can be made up of anyone as long as they fit the criteria of the specific trial and can grant consent for their participation.

Q: Are there risks to participating in a trial?
A: The nature of these investigations is such that they sometimes do involve a degree of risk for participants. Risk levels vary depending on the trial, but they can’t be completely ruled out.

Low Testosterone in Men – Symptoms and Diagnosis

The recipient of a DO from the Western University of Health Sciences, Dr. Hanid Audish is a principal investigator of clinical research at Encompass Clinical Research. Dr. Hanid Audish has conducted several clinical trials on the effects of new drugs on various health conditions, including low testosterone and hypertension.

Secreted by the testicles in men, testosterone is a hormone that is mainly associated with secondary sexual attributes, including sperm production and sex drive. The hormone also plays a significant role in various changes associated with puberty, such as an increase in muscle size and bone mass. Generally, testosterone production is continuous throughout the life of a man, although the production rate peaks during early adulthood, and gradually decreases as a person gets older. A blood test known as a serum test is used to check the level of testosterone. In men, normal testosterone levels range from 300 to 1000 nanogram per deciliter.

A report from the American Urological Association showed that approximately 2 out of 10 men above the age of 60 have low testosterone. Low testosterone (Low T) is characterized by testosterone levels falling below 300 nanograms per deciliter.

Low T can be associated with a wide range of symptoms in men. Increased body fat, loss of muscle mass, difficulty obtaining an erection, and low sex drive can arise from low testosterone. According to a paper published in the Journal of the American Medical Association, low T can result in an increased risk of anemia in men. During the study, testosterone gels were administered to anemic men, and significant improvement was recorded.

Important Comorbidities of Diabetes to Look out for

A principal investigator at Encompass Clinical Research, Dr. Hanid Audish is a physician specializing in clinical research. At Encompass, Dr. Hanid Audish oversees research into osteoarthritis and diabetes, two conditions that he became intimately familiar with in his prior family medicine practice.

Diabetes is a chronic condition, and it can affect many systems throughout the body. People who are suffering from diabetes are well-advised to adopt a series of measures that can reduce its effects and potentially even reverse it. However, diabetes can indirectly cause or contribute to other conditions that should be monitored frequently.

One of the most common comorbidities of diabetes is high blood pressure, which occurs in 75 percent of adults that present diabetic symptoms. This can, in turn, cause its own series of chronic conditions.

Unusually high or low blood lipids also frequently afflict diabetics, and this imbalance shares many of the same risk factors as diabetes. Like type 2 diabetes, dyslipidemia is closely tied to lifestyle factors and should be addressed in conjunction with diabetic symptoms. Other comorbidities include sleep apnea and fatty liver disease.

Clinical research is ongoing into diabetes and it’s comorbidities. If you would like to learn more about clinical trials investigating diabetes, please visit www.encompassresearch.com or www.drhanidaudish.com.

Male Hypogonadism – Symptoms and Treatment

The recipient of a doctor of osteopathy degree from the Western University of Health Sciences in California, Dr. Hanid Audish is a physician and clinical investigator at Encompass Clinical Research. Dr. Hanid Audish has contributed to the success of clinical trials addressing various medical conditions, including male hypogonadism and diabetes.

Male hypogonadism is a condition characterized by the inability to produce adequate testosterone, a hormone essential for masculine development and growth during puberty. The condition can be inherited or acquired through accidents or infections, and its treatment typically involves testosterone replacement therapy. Male hypogonadism presents various symptoms in affected males.

The development of hypogonadism can occur during the fetal stage, puberty, or adulthood, and the period of its occurrence determines the type of symptoms that a patient exhibits. During the fetal stage, an interrupted growth of the sex organs is common. Affected male children are usually born with female genitals, ambiguous genitals, or under-formed male genitals. During puberty, it delays voice deepening, muscle development, facial hair growth, and genital formation. In adulthood, symptoms include low sex drive, lack of energy, and depression. These symptoms can worsen over time to erectile dysfunction, infertility, and loss of muscle mass and bone mass.

In most cases, male hypogonadism is treated with testosterone replacement therapy. This therapy is available in different forms, including injections and implants, gels, mouth patches, and skin patches. Restoring sex drive, normalizing growth hormones, and restoring fertility are the three main functions of this therapy.